Making Early Disease Detection Possible
Discover how VeraBIND is redefining diagnostics.
At Veravas, we are transforming the future of laboratory diagnostics. Our patented VeraBIND™ technology is designed to overcome long-standing challenges in the industry by eliminating interferences and accurately detecting low-abundance biomarkers, resulting in early detection and improved outcomes.
Featured Solution: VeraBIND Tau
Our latest application for VeraBIND™ is in the early detection of tau pathology associated with Alzheimer’s disease (AD). The tau protein is one of the hallmark proteins of AD and early detection of such biomarkers is a crucial area of research.1
Advanced Research Solutions for Early Disease Detection
VeraBIND:
VeraBIND tests and pre-treatment solutions provide breakthrough capabilities in detecting and analyzing biomarkers of interest, with a focus on enhanced assay sensitivity and reliable detection. Our innovative technology enhances sample preparation, and provides accurate, and reproducible results across a wide range of diseases.
Regardless of sample type or biomarker of interest, VeraBIND technology offers the reliability and accuracy needed to accelerate research to make impactful discoveries, perform liquid biopsies, or improve test accuracy.
Thal DR, Tomé SO. The central role of tau in Alzheimer's disease: From neurofibrillary tangle maturation to the induction of cell death. Brain Res Bull. 2022;190:204-217. doi:10.1016/j.brainresbull.2022.10.006 https://pubmed.ncbi.nlm.nih.gov/36244581/